ETRA · Why this verdict
Why Electra Therapeutics (ETRA) is rated SELL
Updated
Model-generated analysis — not investment advice. Not a registered investment advisor. Past performance does not guarantee future results. How we score · Editorial policy
Show full disclosure ▾Hide full disclosure ▴
About TrendMatrix. TrendMatrix is a publisher of general securities research and market commentary. We publish on a regular schedule. All content is the same for every subscriber in a tier — we do not provide personalized investment advice and we do not take into account any individual subscriber's financial situation, investment objectives, risk tolerance, tax situation, or holdings.
Not investment advice. TrendMatrix is not a registered investment adviser. Our content is for informational and educational purposes only. Consult your own licensed investment adviser, broker, or tax professional before making any investment decision.
Conflicts and positions. People who build TrendMatrix, or entities they control, may hold positions, long or short, in securities it covers, and may trade them at any time. Positions are not disclosed individually. Verdicts are generated by an automated model applied by the same rules to every covered stock, and are not adjusted for any position held by the people who build TrendMatrix. We do not accept payment from issuers for coverage.
No paid promotion. TrendMatrix does not accept payment from any issuer, broker, or third party in exchange for coverage of any security.
No fiduciary duty. No fiduciary, advisory, or agency relationship is created between you and TrendMatrix by reading our content or subscribing to our service.
Performance. Past performance is not indicative of future results. Performance figures reflect the published model only and do not reflect any individual subscriber's actual results.
VerdictSELL
Overall score5.5/10
ConfidenceMEDIUM
MacroNEUTRAL
TrendMatrix Research · core thesis
Engine thesis — one sentence
Electra Therapeutics is a speculative biotech with no reported margins and below-average business quality, but insiders bought about $40.0M (7.05% of market cap) in 90 days with no sales, a strong show of conviction. Price data was unavailable this run, so no trade setup exists.
Falsifiable statement — pillar-level invalidators below. Engine-derived; not personalized advice.
Thesis pillars
| Pillar | Expectation | Trend |
|---|---|---|
The engine classifies Binary industry: Biotechnology as speculative, so outcomes hinge on clinical events rather than current financials, which show 0.0 gross, operating and net margin scores. Suitability rationale | Position stays small and speculative until clinical or revenue evidence lifts the quality score from 2.6. | →Stable |
| CounterA single positive clinical readout could re-rate the stock sharply and make the speculative classification look overly cautious. | ||
Insiders made 4 purchases totaling about $40.0M (7.05% of market cap) in the last 90 days with zero sales, signalling strong management conviction. Insider breakdown | Insider net buying stays positive and no open-market insider selling appears over the next 12 months. | →Stable |
| CounterThe purchases may reflect a single financing-related allocation rather than a repeated discretionary signal, and insider buying does not de-risk binary clinical outcomes. | ||
The current ratio score of 5.6 indicates short-term assets comfortably cover near-term obligations, giving the company runway to fund development. Components | Liquidity remains strong enough that no near-term dilutive raise is forced over 12 months. | →Stable |
| CounterPre-revenue biotechs burn cash steadily, so a high current ratio today can erode quickly and lead to dilutive financing. | ||
Quality concerns are flagged: the quality score is 2.6 with moat at 5.5 and Piotroski F at 4.4, so the business is below average on fundamentals. Key risks | Quality score improves from 2.6 as the pipeline matures, or the below-average label persists. | →Stable |
| CounterStandard quality metrics penalize pre-revenue biotechs structurally, so the low score may say little about pipeline value. | ||
No clear chart pattern is present and technical signals are mixed, while momentum at 5.0 only just clears the engine's 4.5 minimum, so there is no identified edge. Chart pattern detection | Momentum holds above the 4.5 threshold and a clearer setup emerges over the coming quarters. | →Stable |
| CounterA mixed chart in a news-driven biotech can flip abruptly on a catalyst, so the lack of a pattern may be irrelevant. | ||
The engine classifies Binary industry: Biotechnology as speculative, so outcomes hinge on clinical events rather than current financials, which show 0.0 gross, operating and net margin scores.
→StableSuitability rationale
- Expectation
- Position stays small and speculative until clinical or revenue evidence lifts the quality score from 2.6.
CounterA single positive clinical readout could re-rate the stock sharply and make the speculative classification look overly cautious.
Insiders made 4 purchases totaling about $40.0M (7.05% of market cap) in the last 90 days with zero sales, signalling strong management conviction.
→StableInsider breakdown
- Expectation
- Insider net buying stays positive and no open-market insider selling appears over the next 12 months.
CounterThe purchases may reflect a single financing-related allocation rather than a repeated discretionary signal, and insider buying does not de-risk binary clinical outcomes.
The current ratio score of 5.6 indicates short-term assets comfortably cover near-term obligations, giving the company runway to fund development.
→StableComponents
- Expectation
- Liquidity remains strong enough that no near-term dilutive raise is forced over 12 months.
CounterPre-revenue biotechs burn cash steadily, so a high current ratio today can erode quickly and lead to dilutive financing.
Quality concerns are flagged: the quality score is 2.6 with moat at 5.5 and Piotroski F at 4.4, so the business is below average on fundamentals.
→StableKey risks
- Expectation
- Quality score improves from 2.6 as the pipeline matures, or the below-average label persists.
CounterStandard quality metrics penalize pre-revenue biotechs structurally, so the low score may say little about pipeline value.
No clear chart pattern is present and technical signals are mixed, while momentum at 5.0 only just clears the engine's 4.5 minimum, so there is no identified edge.
→StableChart pattern detection
- Expectation
- Momentum holds above the 4.5 threshold and a clearer setup emerges over the coming quarters.
CounterA mixed chart in a news-driven biotech can flip abruptly on a catalyst, so the lack of a pattern may be irrelevant.
Per-dimension breakdown
Quality
2.6/10data confidence 86%| Component | Sub-score |
|---|---|
| Gross margin | 0.0 |
| Op margin | 0.0 |
| Net margin | 0.0 |
| Current ratio | 5.6 |
| Moat | 5.5 |
| Piotroski F | 4.4 |
- ▸Quality concerns
Growth
5.0/10data confidence 50%Momentum
4.2/10data confidence 100%| Component | Sub-score |
|---|---|
| RSI | 4.5 |
| MACD | 7.0 |
| OBV | 5.8 |
| MA position | 3.5 |
| Volume | 0.0 |
Sentiment
7.6/10data confidence 100%| Component | Sub-score |
|---|---|
| LLM sentiment | 5.8 |
| Analyst rating | 7.3 |
| Price target | 10.0 |
- ▸Light analyst coverage (5.0) — signal dampened
- ▸Analyst upside: 270%
Insider
8.5/10data confidence 100%| Component | Sub-score |
|---|---|
| materiality | 9.0 |
| insider conviction | 8.0 |
| holder change | 10.0 |
| notable moves | 7.0 |
- ▸Heavy insider buying — $39,999,990 (7.097% of mkt cap)
- ▸Institutions accumulating
Peer rank
5.4/10data confidence 80%| Component | Sub-score |
|---|---|
| value rank | 5.0 |
| quality rank | 5.0 |
| growth rank | 5.0 |
Technical
5.2/10data confidence 100%| Component | Sub-score |
|---|---|
| bollinger | 5.6 |
| support resistance | 7.8 |
| 52w position | 1.6 |
| gap | 6.0 |
Risk (lower is worse)
6.6/10data confidence 60%| Component | Sub-score |
|---|---|
| days to cover | 10.0 |
| volatility | 0.0 |
| debt equity | 9.9 |
Catalyst
8.0/10data confidence 25%| Component | Sub-score |
|---|---|
| news activity | 8.0 |
How the verdict was assembled
Engine trigger
Quality below minimum threshold.
Engine technical detail
verdict_path:
L1:HARD_BLOCK:QUALITY_FLOORPassed (6)
- INSIDER:OK
- 8K:CLEAN
- NEWS_EVENTS:NONE_RECENT
- EARNINGS_PROXIMITY:NO_DATE
- SEMI_CYCLE_PEAK:CLEAR
- MATERIALS_CYCLE_PEAK:CLEAR
Failed (1)
- MOMENTUM:4.2<4.5
Warning (1)
- ASYMMETRY:UPSIDE_EXHAUSTED (upside=0.0%)
Reward-to-Risk
0.00
Upside
+0.0%
Downside
15.0%
Sizing output
AVOID
SetupRange Bound — RSI 48 mid-range, Bollinger mid-band
EdgeNo clear edge — No clear edge identified
SuitabilitySpeculative — Drawdown -42% (>40% off 52w high), Binary industry: Biotechnology
Investment implication
The SELL_IF_HOLDING verdict reflects the MOMENTUM gate's 4.2<4.5 outcome against Insider at 8.5 and asymmetric R:R of 0.00.
The strongest dimensions are Insider at 8.5, Catalyst at 8.0, and Sentiment at 7.6; the weakest are Quality at 2.6, Momentum at 4.2, and Growth at 5.0. The V9 engine flagged 1 failed gate with 1 warning, producing an asymmetric reward-to-risk of 0.00 and an engine sizing output of AVOID.
What would invalidate the thesis
Falsifying conditions — when triggered, the corresponding pillar's thesis is invalidated.
- P1Heavy Insider Buying Conviction
Trip ifInsider selling exceeds $5M in any 90-day window after the $40.0M of purchases.
- P2Binary Biotech Speculative Profile
Trip ifQuality score rises above 5.0 from current 2.6, which would weaken the speculative classification.
- P3Strong Liquidity Cushion
Trip ifCurrent ratio falls below 2.0 from current 5.6.
- P4Below Average Business Quality
Trip ifQuality score rises above 5.0 from current 2.6 for 2 consecutive quarters.
- P5Mixed Technical Setup No Edge
Trip ifMomentum score falls below 4.5 from current 5.0.